Articles
7,692 Articles
Psychedelic Invest
/
Dec 23, 2024
Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing...
Psychedelic Invest
/
Dec 23, 2024
Psyence Biomed Announces $2.0 Million Private Placement
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu...
Psychedelic Invest
/
Dec 23, 2024
PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased...
MDMA
Psychedelics Today
/
Dec 20, 2024
The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State
What can we learn from the mystical roots of psychedelics? And what can we learn from dreams? In this episode, Joe interviews Shauheen Etminan, Ph.D.: co-founder of VCENNA, a drug discovery and development company, and Magi Ancestral Supplements, which sells nootropics inspired by ancient Eastern...
Psychedelic Invest
/
Dec 20, 2024
Jaguar Health Announces Import of Coca Leaf from Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
SAN FRANCISCO – Jaguar Health, Inc.(NASDAQ: JAGX) (‘Jaguar’) today announced that Magdalena Biosciences, Inc. (‘Magdalena’), a joint venture formed by Jaguar and Filament Health Corp. (OTCQB: FLHLF)(Cboe CA: FH)(FSE: 7QS) (‘Filament’ or ‘Filament Health’), successfully...
Psychedelics Today
/
Dec 20, 2024
Psychedelics Today Gifting Guide 2024
As the holiday season rolls around, the timeless tradition of giving takes on new meaning within the psychedelic community. Whether you’re searching for something thoughtful, practical, or just downright fun, this guide celebrates how we can honor our friends, loved ones, and even ourselves. From...
Psychedelic Invest
/
Dec 19, 2024
Psyence Biomedical : Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial Form 6K
NEW YORK, December 17, 2024 — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today highlighted recent progress that has been made with its active Phase IIb clinical trial of nature derived psilocybin, in conjunction with psychotherapy, as a potential treatment...
DoubleBlind Mag
/
Dec 19, 2024
Here Are the 9 Most Iconic TV Scenes About Psychedelics
Not everyone is open about using psychedelics, but you may be surprised by how many people — including your favorite TV show creators — have been inspired by them. Psychedelic trips have appeared on TV for decades, from scenes explicitly about shrooms or acid to those that present them under the...
Psychedelics
Psilocybin Alpha
/
Dec 18, 2024
Pα+ Psychedelic Bulletin #183: UW Madison’s Psychedelic Symposium; MindMed Doses First Phase 3 Patient; Beckley’s IV Psilocin Readout; Psilocybin for COVID Clinicians
Members of the Psychedelic Alpha team Josh Hardman and Noah Smith, as well as Editor-at-Large Graham Pechenik, had a great time attending the fourth annual UW Madison Psychedelic Symposium last month. The UW Madison psychedelics folks are fantastic hosts, and we particularly enjoyed an insight into...
Psilocybin
Psychedelic Invest
/
Dec 18, 2024
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today...
Psychedelic Invest
/
Dec 18, 2024
Awakn Life Sciences Announces Credit Facility
Toronto, Ontario–(Newsfile Corp. – December 18, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to announce that...
DoubleBlind Mag
/
Dec 18, 2024
Willy Myco Just Released the First-Ever Video Demonstrating How to Synthesize LSD
The process for synthesizing Lysergic Acid Diethylamide (LSD), more commonly known as “acid,” has long been shrouded by complex chemistry jargon, not to mention laws discouraging anybody from posting the process online lest they incur serious legal consequences. As such, learning how to make LSD...
LSD
Psychedelic Invest
/
Dec 17, 2024
Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc
Toronto, Ontario–(Newsfile Corp. – December 16, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company“) a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to announce that...
DoubleBlind Mag
/
Dec 17, 2024
The Evolution of Modern Psychedelic Art
I am staring ahead at two tigers leaping through the sky, approaching a naked woman who is lying blissfully unaware on a floating block of ice. It is Dali’s famous 1944 painting, succinctly titled, “Dream Caused by the Flight of a Bee Around a Pomegranate a Second Before Awakening.” A year...
LSD
Ayahuasca
Psychedelic Invest
/
Dec 17, 2024
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health...
Psychedelic Invest
/
Dec 17, 2024
Numinus Provides Bi-Weekly Update on Annual Filings
VANCOUVER, BC, Dec. 16, 2024 /PRNewswire/ – Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (“Numinus” or the “Company“), a leader in mental health care specializing in innovative and evidence-based treatments, today provided an update with respect to its previously announced...
Psychedelic Invest
/
Dec 17, 2024
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed’s Phase IIb Palliative Care Trial
Vancouver, British Columbia–(Newsfile Corp. – December 17, 2024) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a Canadian manufacturer of GMP-certified, naturally-derived psilocybin and MDMA, has entered into binding agreements with Psyence...
Psilocybin
Psychedelic Invest
/
Dec 17, 2024
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a...
Psychedelic Invest
/
Dec 17, 2024
Numinus Wellness Closes Sale of Clinics and Launches Initiative to Increase Access to Mental Health Care
VANCOUVER, BC, Dec. 17, 2024 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23), a mental healthcare company advancing traditional and innovative behavioral health treatments including safe, evidence-based psychedelic-assisted...
Psychedelics Today
/
Dec 17, 2024
Transpersonal Connections, the Body’s Memory, and the Collaborative Nature of Consciousness
In this episode, Joe interviews Paul Grof: research psychiatrist, clinician, author, brother of Stanislav, professor of psychiatry at the University of Toronto, and director of the Ottawa Mood Disorders Center. He talks about his extensive career in psychiatry, and how trying to understand the cause...
Psychedelic Invest
/
Dec 17, 2024
Filament Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences
VANCOUVER, BC, Dec. 16, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or “Filament Health”), a clinical-stage natural psychedelic drug development company, today announced that Magdalena Biosciences (“Magdalena”), a joint venture formed by...
Psychedelics - Green Market Report
/
Dec 16, 2024
Graft Polymer to buy Awakn Life Sciences in all stock deal
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) announced it would be bought by Graft Polymer (UK) PLC with Graft acquiring all of the company’s shares in a deal valued at C$8.8 million. Graft is a UK-based biotechnology company listed on the London Stock Exchange under the symbol “GPL”...
Psychedelics Today
/
Dec 13, 2024
The War on Drugs: The DEA’s Attempt to Schedule DOI & DOC and the Fight for Sensible Policy
Whether you’re a drug user or not, society as a whole has been hurt tremendously by the War on Drugs. Can we win the battle with education and sensible policy? In this episode, Joe interviews Kat Murti: executive director of Students for Sensible Drug Policy (SSDP), the largest nationwide network...
Psychedelic Invest
/
Dec 13, 2024
PharmAla Announces Private Placement
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased...
MDMA
DoubleBlind Mag
/
Dec 12, 2024
Good Vibrations: The Top 25 Psychedelic Rock Albums
Psychedelic music had simple yet complex beginnings: All you had to do to call yourself a psych-rock artist back in the mid-to-late 1960s was put a tab of LSD on your tongue, wait an hour, then crank up the amplifier and bang out some bluesy riffs on an electric guitar. The counterculture movement...
LSD
Psychedelic Invest
/
Dec 12, 2024
MindBio Announces Arrangements to Address Mailing Delays Resulting from Canada Post Strike
Vancouver, British Columbia – December 11, 2024 –TheNewswire –MindBio Therapeutics Corp.(the “Company” or “MindBio”) (CSE: MBIO) (Frankfurt:WF6) wishes to provide an update to its shareholders on the impact of the strike by the Canadian Union of Postal Workers on the Company’s...
Psychedelic Invest
/
Dec 11, 2024
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
Toronto, Ontario–(Newsfile Corp. – December 10, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, today announces initial...
DoubleBlind Mag
/
Dec 10, 2024
Should Psychedelic Researchers Disclose Personal Use of the Drugs They Study?
Scientific researchers who author papers must disclose any financial conflicts of interest when publishing their studies — like if they’re employed by companies that might profit from the subject matter being investigated. Psychedelic researchers, however, are not required to admit whether they...
Psychedelics Today
/
Dec 10, 2024
The Potential of Buprenorphine, the Risks of Ketamine, and How Psychedelics Could Prevent Nuclear War
In this episode, Joe interviews Howard Kornfeld, MD: renowned pain medicine expert, addiction specialist, early pioneer in psychedelic medicine, and currently the director of recovery medicine at Recovery Without Walls. As a leader in the utilization of buprenorphine, he talks about how it came...
Psychedelics
Psychedelic Invest
/
Dec 10, 2024
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has progressed beyond the previously-announced non-binding Letter of Intent (LOI) and executed binding agreements with Optimi Health Corp. Under...
Psilocybin Alpha
/
Dec 10, 2024
Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding
As some of us draw up our wishlists for Santa’s perusal (though, apparently Saint Nicholas has been found a little worse for wear in Turkey), some psychedelics insiders are noting down their hopes for the incoming Trump administration. Since the U.S. elections last month, I have been speaking with...
Psilocybin
Psychedelics
Psychedelic Invest
/
Dec 10, 2024
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the presentation of two posters...
DMT
Psychedelics - Green Market Report
/
Dec 09, 2024
Relmada halts depression drug trials, shifts focus to psilocybin program amid review
Relmada Therapeutics Inc. (Nasdaq: RLMD) will halt its Phase 3 studies of depression treatment REL-1017 following a data monitoring committee evaluation, sending the company searching for strategic alternatives. The late-stage biotechnology company will discontinue both the Reliance II and Relight...
DoubleBlind Mag
/
Dec 09, 2024
The First Major For-Profit Psychedelic Company Is Experiencing Major Setbacks
When the FDA denied MDMA-assisted therapy earlier this year, the shockwaves throughout the psychedelic industry were immediate and apparent. Now, Compass Pathways, another major player in the space, has announced that it is laying off roughly 30% of its workforce and delaying the Phase 3 Trials for...
MDMA
DoubleBlind Mag
/
Dec 09, 2024
Santo Daime Ayahuasca Church Faces a “Me Too” Reckoning
In Rio de Janeiro, a woman is bringing a lawsuit against a prominent Santo Daime leader named Paolo Roberto for sexual assault under the guise of therapy. He is a fixture of a Santo Daime church in Rio de Janeiro and a senior figure in one particular lineage of Santo Daime, with many supporters and...
Ayahuasca
Psychedelic Invest
/
Dec 09, 2024
Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central...
